The updated dataset consists of 63 multiple myeloma patients.

95% overall response rate (36 of 38 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma who were not exposed to prior BCMA-targeted therapy, producing a median progression-free survival (mPFS) of 12.9 months.

Also Read: Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis.

90% overall response rate (45 of 50 patients at the therapeutic dose of 800 million CAR+T cells) in relapsed/refractory multiple myeloma.

58% complete response rate (29 out of 50 patients at the therapeutic dose of 800 million CAR+T cells)

The overall response rates for each dose level were 50%, 86%, and 90%, respectively.

Favorable NXC-201 safety data support the potential for NXC-201, if ultimately approved, to reduce hospitalization, with an opportunity for use as outpatient CAR-T cell therapy, potentially reducing related hospitalization costs by up to 80%.

Price Action: IMMX shares are up 23.40% at $4.22 on the last check Monday.